Skip to content

Exagen Inc. XGN Current maturities of long-term debt

Current maturities of long-term debt at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s current maturities of long-term debt?
Exagen Inc. (XGN) reported current maturities of long-term debt of $1.11M in Q1 2026.
What is the long-term trend for Exagen Inc.'s current maturities of long-term debt?
Over 4 years (2021 to 2025), Exagen Inc.'s current maturities of long-term debt has grown at a 17.9% compound annual growth rate (CAGR), from $587K to $1.14M.